The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?

approximately $1,620,721 rather than the actual price of $62,394. The correct answer for Avonex is a more modest 12% annual change (note that the error is greater the more years since a product launch). CPI calculation errors are much smaller so that the differences between drug and CPI changes are also not maintained when corrected. Thus the difference from CPI is also more modest. While these corrected price increases (and differences from CPI increases) may still suggest further exploration, a 12% annual price increase is not as striking as the claimed 34.6%.